Tvardi Therapeutics, Inc. (TVRD)
$1.04-1.89%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $10M
- Beta
- 0.37
- P/E (TTM)
- -0.37
- Short % float
- 3.69%
- Days to cover
- 1.0
- SI change
- -12.2%
- 1W
- -3.70%
- 1M
- -43.17%
- vs SPY 1W
- -3.57%
- vs SPY 1M
- -45.68%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 21
- VALUE
- 30
- GROWTH
- 45
- GARP
- 5
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-87.2%
REV YoY-
ROE-145.4%
EPS YoY-
ROA-148.8%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.37
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.16
P/FCF-
EV/EBITDA0.22
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.73
ALTMAN Z-
CURR RATIO1.87
ND/EBITDA-
BETA0.37
Company news
FAQ
- What is LOPJLB’s current signal on TVRD?
- LOPJLB’s latest quantitative signal on Tvardi Therapeutics, Inc. (TVRD) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TVRD in?
- Tvardi Therapeutics, Inc. (TVRD) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Tvardi Therapeutics, Inc. (TVRD) do?
- Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical…